Thymosin β4 for the treatment of acute stroke in aged rats.

Morris DC, Cheung WL, Loi R, Zhang T, Lu M, Zhang ZG, Chopp M

Neuroscience letters31 Aug 2017Cited by 10 (Europe PMC)

PMID28864242PMCIDPMC5624853DOI10.1016/j.neulet.2017.08.064PepBankPUB-28864242

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In aged rats with embolic stroke, Tβ4 reduced infarct volume by more than 50% compared with control.
In plain wordsIn aged rats with stroke, thymosin beta‑4 cut the size of the brain damage by more than half compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseInfarct volume
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Measurements
Infarct volume
12.8%
Tβ4
Infarct volume
26%
control
Source sentences
Summary
The Tβ4 treatment reduced infarct volume by more than 50% (12.8%±9.3%, mean±SE, p<0.05) compared to the control group (26.0%±4.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424201
02AnimalAnimal study (in vivo)Efficacy outcome
In aged rats with embolic stroke, Tβ4 did not improve functional outcome compared with control.
In plain wordsIn aged rats with stroke, thymosin beta‑4 did not improve movement and neurological tests compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeFunctional outcome (ART, FFT, mNSS)
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Source sentences
Summary
However, Tβ4 did not show improvement in functional outcome compared to control.
3 context sentences(design, population, supporting numbers)
Summary · context
Functional tests (adhesive-removal test (ART), foot fault test (FFT) and the modified Neurological Severity Score (mNSS)) were performed weekly.
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424202
03AnimalAnimal study (in vivo)Efficacy outcome
In aged rats with embolic stroke, Tβ4 caused no significant increase in oligodendrogenesis compared with control.
In plain wordsIn aged rats with stroke, thymosin beta‑4 did not significantly increase new oligodendrocyte formation compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeOligodendrogenesis
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Source sentences
Summary
There was no significant increase in oligodendrogenesis, myelination and gliosis between control and treatment with Tβ4
2 context sentences(design, population, supporting numbers)
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424203
04AnimalAnimal study (in vivo)Efficacy outcome
In aged rats with embolic stroke, Tβ4 caused no significant increase in myelination compared with control.
In plain wordsIn aged rats with stroke, thymosin beta‑4 did not significantly increase myelination compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeMyelination
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Source sentences
Summary
There was no significant increase in oligodendrogenesis, myelination and gliosis between control and treatment with Tβ4
2 context sentences(design, population, supporting numbers)
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424204
05AnimalAnimal study (in vivo)Efficacy outcome
In aged rats with embolic stroke, Tβ4 caused no significant increase in gliosis compared with control.
In plain wordsIn aged rats with stroke, thymosin beta‑4 did not significantly increase gliosis compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeGliosis
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Source sentences
Summary
There was no significant increase in oligodendrogenesis, myelination and gliosis between control and treatment with Tβ4
2 context sentences(design, population, supporting numbers)
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424205
06AnimalAnimal study (in vivo)Safety outcome
In aged rats with embolic stroke, three deaths occurred in each of the control and Tβ4 groups after randomization.
In plain wordsIn aged rats with stroke, the same number of deaths occurred in the control and thymosin beta‑4 groups.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeDeaths after randomization
Study
ratn = 23
Aged rat embolic MCAo stroke
Comparator
Control
Outcome group
Mortality · Whole body
Studied dose
12 mg/kg · first dose 24 h after MCAo, then every 3 days for 4 additional dosesAs given in this study (rat).
Source sentences
Summary
After randomization, there were three deaths in both the control and Tβ4 groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Aged Male Wistar rats (Charles River, France 18-21 months) were subjected to embolic middle cerebral artery occlusion (MCAo).
Summary · context
Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24h after MCAo and then every 3days for 4 additional doses.
Report a problemFND-2886424206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.